Covered recipient · General Payments record
WAJEEHA YOUSAF
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$1,769.85
77 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,769.85 | 77 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $715.66 | 27 |
| Janssen Biotech, Inc. | $360.99 | 16 |
| AstraZeneca Pharmaceuticals LP | $256.37 | 14 |
| Amgen Inc. | $81.93 | 4 |
| Horizon Therapeutics plc | $65.22 | 4 |
| UCB, Inc. | $61.64 | 3 |
| Alexion Pharmaceuticals, Inc. | $50.89 | 1 |
| Novartis Pharmaceuticals Corporation | $44.26 | 2 |
| GlaxoSmithKline, LLC. | $35.94 | 2 |
| Octapharma USA, Inc. | $32.14 | 1 |
| Aurinia Pharma U.S., Inc. | $27.48 | 1 |
| Mallinckrodt Hospital Products Inc. | $22.03 | 1 |
| Hikma Pharmaceuticals USA | $15.30 | 1 |
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WAJEEHA YOUSAF
NPI 1770715765 · CMS profile ID 170886
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WAJEEHA YOUSAF, NPI 1770715765, CMS profile ID 170886. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). WAJEEHA YOUSAF, NPI 1770715765, CMS profile ID 170886. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- WAJEEHA YOUSAF, NPI 1770715765, CMS profile ID 170886, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
77 matching records · $1,769.85 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–77 of 77.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $25.00 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933776703 | CMS |
| Janssen Biotech, Inc. | $28.48 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886619007 | CMS |
| ABBVIE INC. | $26.47 | 05/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255281 | CMS |
| ABBVIE INC. | $25.45 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255279 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.01 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914886067 | CMS |
| Horizon Therapeutics plc | $18.86 | 05/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937715151 | CMS |
| Janssen Biotech, Inc. | $22.17 | 05/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886619001 | CMS |
| ABBVIE INC. | $28.14 | 04/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255277 | CMS |
| Hikma Pharmaceuticals USA | $15.30 | 04/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927083135 | CMS |
| Janssen Biotech, Inc. | $15.82 | 04/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886618995 | CMS |
| ABBVIE INC. | $119.87 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255275 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.89 | 03/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915469679 | CMS |
| ABBVIE INC. | $28.52 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255273 | CMS |
| ABBVIE INC. | $25.09 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255271 | CMS |
| Aurinia Pharma U.S., Inc. | $27.48 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954108321 | CMS |
| ABBVIE INC. | $23.12 | 03/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255269 | CMS |
| Amgen Inc. | $14.23 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939343501 | CMS |
| GlaxoSmithKline, LLC. | $16.08 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944821817 | CMS |
| ABBVIE INC. | $25.39 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255267 | CMS |
| Octapharma USA, Inc. | $32.14 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937558835 | CMS |
| Amgen Inc. | $22.36 | 02/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939343499 | CMS |
| Janssen Biotech, Inc. | $18.11 | 02/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886618987 | CMS |
| ABBVIE INC. | $15.09 | 02/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255265 | CMS |
| ABBVIE INC. | $22.61 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255263 | CMS |
| ABBVIE INC. | $26.59 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255261 | CMS |
| AstraZeneca Pharmaceuticals LP | $63.56 | 01/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914793999 | CMS |
| ABBVIE INC. | $18.07 | 01/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893255259 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,068,306.54 | 110 |
| PY2024 | Principal investigator | $180,496.46 | 4 |
| PY2023 | Principal investigator | $19,092.66 | 4 |
| PY2022 | Principal investigator | $21,836.00 | 5 |
| PY2021 | Principal investigator | $5,568.88 | 15 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
110 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 12/24/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155453 |
| Principal investigator 1 | ARGENX US, INC. | $4,859.00 | 12/24/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155464 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,617.31 | 12/17/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289912 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,195.57 | 12/17/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289914 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,700.35 | 12/01/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289142 |
| Principal investigator 1 | UCB SA | $27,667.00 | 11/27/2025 | Non-covered Recipient Entity Novel Research Llc | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246656866 |
| Principal investigator 1 | ARGENX US, INC. | $9,027.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155377 |
| Principal investigator 1 | ARGENX US, INC. | $9,027.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155381 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155387 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155391 |
| Principal investigator 1 | ARGENX US, INC. | $2,444.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155396 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155399 |
| Principal investigator 1 | ARGENX US, INC. | $2,720.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155403 |
| Principal investigator 1 | ARGENX US, INC. | $4,859.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155406 |
| Principal investigator 1 | ARGENX US, INC. | $2,444.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155410 |
| Principal investigator 1 | ARGENX US, INC. | $2,720.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155414 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155417 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155421 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155425 |
| Principal investigator 1 | ARGENX US, INC. | $2,622.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155460 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155473 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 11/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155478 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $24,808.26 | 11/19/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288597 |
| Principal investigator 1 | ARGENX US, INC. | $8,393.00 | 10/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155467 |
| Principal investigator 1 | ARGENX US, INC. | $2,622.00 | 10/20/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155470 |
| Principal investigator 1 | ARGENX US, INC. | $2,622.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155374 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155428 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155431 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155435 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155438 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155441 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155446 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155449 |
| Principal investigator 1 | ARGENX US, INC. | $8,393.00 | 10/02/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155457 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,288.60 | 09/17/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223285594 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,044.02 | 09/17/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223285596 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $66,369.68 | 09/15/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL | No dispute reported | 06/30/2026 | 1190311937 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155580 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155587 |
| Principal investigator 1 | ARGENX US, INC. | $4,859.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155591 |
| Principal investigator 1 | ARGENX US, INC. | $4,859.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155595 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155599 |
| Principal investigator 1 | ARGENX US, INC. | $6,519.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155602 |
| Principal investigator 1 | ARGENX US, INC. | $2,622.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155606 |
| Principal investigator 1 | ARGENX US, INC. | $2,720.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155610 |
| Principal investigator 1 | ARGENX US, INC. | $2,720.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155613 |
| Principal investigator 1 | ARGENX US, INC. | $9,027.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155620 |
| Principal investigator 1 | ARGENX US, INC. | $9,027.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155624 |
| Principal investigator 1 | ARGENX US, INC. | $941.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155629 |
| Principal investigator 1 | ARGENX US, INC. | $8,350.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155632 |
| Principal investigator 1 | ARGENX US, INC. | $2,622.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155637 |
| Principal investigator 1 | ARGENX US, INC. | $2,444.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155641 |
| Principal investigator 1 | ARGENX US, INC. | $8,350.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155674 |
| Principal investigator 1 | ARGENX US, INC. | $2,622.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155682 |
| Principal investigator 1 | ARGENX US, INC. | $2,444.00 | 09/04/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155686 |
| Principal investigator 1 | ARGENX US, INC. | $573.00 | 09/03/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155690 |
| Principal investigator 1 | ARGENX US, INC. | $79.50 | 09/03/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155694 |
| Principal investigator 1 | ARGENX US, INC. | $143.20 | 09/03/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155699 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,482.12 | 08/20/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223284395 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,953.58 | 08/19/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) | No dispute reported | 06/30/2026 | 1190311939 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155567 |
| Principal investigator 1 | ARGENX US, INC. | $600.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155571 |
| Principal investigator 1 | ARGENX US, INC. | $2,600.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155644 |
| Principal investigator 1 | ARGENX US, INC. | $16,500.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155647 |
| Principal investigator 1 | ARGENX US, INC. | $2,350.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155652 |
| Principal investigator 1 | ARGENX US, INC. | $3,150.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155657 |
| Principal investigator 1 | ARGENX US, INC. | $250.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155660 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155663 |
| Principal investigator 1 | ARGENX US, INC. | $2,816.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155667 |
| Principal investigator 1 | ARGENX US, INC. | $3,000.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155671 |
| Principal investigator 1 | ARGENX US, INC. | $2,350.00 | 08/13/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155678 |
| Principal investigator 1 | UCB SA | $35,544.05 | 08/13/2025 | Non-covered Recipient Entity Novel Research Llc | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246656604 |
| Principal investigator 1 | ARGENX US, INC. | $350.00 | 07/28/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155575 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,245.00 | 07/25/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283172 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,360.00 | 07/25/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283174 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 07/25/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283176 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 07/25/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283178 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $232.00 | 07/25/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283180 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $58.00 | 07/25/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283182 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,925.11 | 07/23/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223282954 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,867.80 | 07/02/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223282156 |
| Principal investigator 1 | ARGENX US, INC. | $26.50 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155482 |
| Principal investigator 1 | ARGENX US, INC. | $159.00 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155486 |
| Principal investigator 1 | ARGENX US, INC. | $37.60 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155489 |
| Principal investigator 1 | ARGENX US, INC. | $214.80 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155494 |
| Principal investigator 1 | ARGENX US, INC. | $35.80 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155497 |
| Principal investigator 1 | ARGENX US, INC. | $573.00 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155503 |
| Principal investigator 1 | ARGENX US, INC. | $382.00 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155507 |
| Principal investigator 1 | ARGENX US, INC. | $7.70 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155510 |
| Principal investigator 1 | ARGENX US, INC. | $5.25 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155513 |
| Principal investigator 1 | ARGENX US, INC. | $2.80 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155517 |
| Principal investigator 1 | ARGENX US, INC. | $258.00 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155521 |
| Principal investigator 1 | ARGENX US, INC. | $21.35 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155525 |
| Principal investigator 1 | ARGENX US, INC. | $75.20 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155529 |
| Principal investigator 1 | ARGENX US, INC. | $85.40 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155532 |
| Principal investigator 1 | ARGENX US, INC. | $191.00 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155536 |
| Principal investigator 1 | ARGENX US, INC. | $26.50 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155540 |
| Principal investigator 1 | ARGENX US, INC. | $517.50 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155542 |
| Principal investigator 1 | ARGENX US, INC. | $668.50 | 06/18/2025 | Non-covered Recipient Entity Novel Research, LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237155547 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,500.00 | 06/03/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1190312299 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $1,345.00 | 05/12/2025 | Non-covered Recipient Entity Advarra, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243527539 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $460.00 | 05/12/2025 | Non-covered Recipient Entity Advarra, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243527545 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $460.00 | 05/12/2025 | Non-covered Recipient Entity Advarra, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243527552 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,949.61 | 04/01/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1190311943 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $148,936.30 | 03/25/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | No dispute reported | 06/30/2026 | 1190311941 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,000.00 | 03/12/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223276333 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,312.76 | 02/05/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) | No dispute reported | 06/30/2026 | 1190312295 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $184,565.00 | 01/21/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | No dispute reported | 06/30/2026 | 1190312297 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,297.82 | 01/09/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190311935 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $126,035.00 | 01/06/2025 | Non-covered Recipient Entity NOVEL RESEARCH LLC | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190312293 |